Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1411S | ISIN: US0327973006 | Ticker-Symbol: 12X1
Frankfurt
27.06.25 | 09:28
8,300 Euro
+4,48 % +0,356
1-Jahres-Chart
ANAVEX LIFE SCIENCES CORP Chart 1 Jahr
5-Tage-Chart
ANAVEX LIFE SCIENCES CORP 5-Tage-Chart
RealtimeGeldBriefZeit
8,1588,39011:26
8,1588,39011:25

Aktuelle News zur ANAVEX LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Anavex-Aktionäre genehmigen Änderung des Vergütungsplans4
ANAVEX LIFE SCIENCES Aktie jetzt für 0€ handeln
13.06.ANAVEX LIFE SCIENCES CORP. - 8-K, Current Report2
13.05.ANAVEX LIFE SCIENCES CORP. - 10-Q, Quarterly Report14
13.05.Anavex Life Sciences Corp. Q2 Loss Beats Estimates412WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share....
► Artikel lesen
13.05.Anavex Life Sciences GAAP EPS of -$0.13 beats by $0.023
13.05.Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update190Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical...
► Artikel lesen
12.05.An Overview of Anavex Life Sciences' Earnings4
12.05.Anavex Life Sciences Q2 2025 Earnings Preview2
06.05.Anavex Life Sciences Corp.: Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 20257
01.05.Anavex Completes Enrollment For Phase 2 Schizophrenia Trial Of ANAVEX3-71328WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company specializing in central nervous system (CNS) disorders, has completed enrollment for its...
► Artikel lesen
01.05.Anavex schließt Rekrutierung für Schizophrenie-Studie Phase 2 ab8
01.05.Anavex Life Sciences Corp.: Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia133Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully...
► Artikel lesen
23.04.Anavex Life Sciences Corp.: Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board863NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
► Artikel lesen
07.04.Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years13
07.04.H.C. Wainwright maintains $42 target on Anavex stock post-study9
05.04.Anavex Life Sciences Reports Long-Term Blarcamesine Benefits For Early Alzheimer's Patients794WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) announced that more than three years of continuous treatment with blarcamesine (ANAVEX 2-73) significantly improved clinical decline...
► Artikel lesen
05.04.Anavex Life Sciences Corp.: Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease208ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and...
► Artikel lesen
31.03.H.C. Wainwright maintains Anavex Buy rating, $42 target6
17.03.Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus34
12.02.Anavex projects EMA feedback on Alzheimer's drug by year-end 202522
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2